What are the indications, dosing protocol, contraindications, monitoring, and follow‑up recommendations for sublingual immunotherapy (allergy drops) in patients with IgE‑mediated allergic rhinitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sublingual Immunotherapy (Allergy Drops) for Allergic Rhinitis

Sublingual immunotherapy (SLIT) is an effective treatment option for patients with IgE-mediated allergic rhinitis who have inadequate response to pharmacotherapy, with FDA-approved tablet formulations available since 2014, though aqueous formulations remain off-label and lack standardized dosing protocols in the United States. 1

Indications

SLIT should be offered to patients with:

  • Confirmed IgE-mediated allergic rhinitis documented by clinical history AND positive allergy testing (skin prick or specific IgE) 1, 2
  • Inadequate symptom control despite pharmacotherapy with or without environmental controls 1, 2
  • Poor response to medications, unacceptable medication side effects, or desire to avoid long-term pharmacotherapy 3
  • Coexisting allergic rhinitis and asthma 3, 1

Critical prerequisite: Demonstration of clinically relevant specific IgE to the offending allergen(s) is mandatory before initiating any form of immunotherapy 1, 2

Dosing Protocol

FDA-Approved Tablets

  • Grass tablets: 15-25 μg of group 5 major allergen, reduced combined symptoms and medication use by 23-41% 4
  • Ragweed tablets: 12 μg of Ambrosia artemisiifolia 1, reduced symptoms by 26% 4
  • House dust mite tablets: 300 index of reactivity (16 μg D. pteronyssinus 1 + 68 μg D. farinae 1), reduced symptoms by 17-18% 4

Administration

  • Daily dosing at home with allergen held under the tongue for approximately 2 minutes before swallowing 1
  • Pre- and co-seasonal therapy for seasonal allergic rhinitis 2
  • Duration: Minimum 3 years for sustained benefit, with ongoing treatment based on patient response 2, 5, 6

Aqueous Formulations (Off-Label)

Important caveat: No FDA-approved aqueous SLIT formulations exist in the United States; dosing is not standardized and use is considered off-label 1, 3

Contraindications and Precautions

Relative Contraindications (Use Caution)

  • Uncontrolled asthma - evaluate before initiating and before each dose 1, 2
  • Beta-blocker use - may increase risk and complicate anaphylaxis treatment 1, 2
  • History of anaphylaxis 2
  • Systemic immunosuppression 2
  • Eosinophilic esophagitis (for SLIT specifically) 2

Age Considerations

  • Children under 5 years: Can be used but requires individualized assessment of cooperation and benefit-risk ratio 3
  • Safety data exists for young children with prospective studies and post-marketing surveillance 3

Pregnancy

  • Generally not initiated during pregnancy, though can be continued if already established 3

Safety Profile

SLIT demonstrates superior safety compared to subcutaneous immunotherapy, with no reported fatalities versus 1 death per 2.5 million SCIT injections 1, 7

Adverse Events

  • Local reactions (most common): Oral itching, throat discomfort, gastrointestinal symptoms - occur in 0.2-97% of patients 1, 5, 8
  • Systemic reactions: 0.056% incidence (significantly lower than SCIT's 0.06-0.9%) 1, 7
  • Anaphylaxis: Extremely rare - only 3 case reports documented 3
    • Two cases involved multiple non-cross-reacting allergens
    • One occurred during latex rush protocol
    • One occurred at peak pollen season after reaching maintenance dose

Critical safety point: Despite low risk, anaphylaxis can occur. First dose should be administered under medical supervision, though subsequent doses can be taken at home 8

Monitoring and Follow-Up

Initial Phase

  • First dose observation: Administer initial dose under medical supervision to monitor for immediate reactions 5
  • Uptitration monitoring: Critical period for safety during dose escalation 5

Ongoing Management

  • Asthma assessment: Evaluate for signs/symptoms of uncontrolled asthma before each administration phase 2
  • Local reactions: Continue escalation or maintenance dosing despite local reactions 2
  • Avoid repeat allergy testing unless there is change in environmental exposures or loss of symptom control 2

Treatment Duration

  • Minimum 3 years of continuous therapy required 2, 5, 6
  • Typical duration 3-5 years for optimal long-term benefit 1
  • Effects persist after discontinuation, distinguishing SLIT from pharmacotherapy 1, 2, 6

Clinical Efficacy

SLIT is supported by systematic reviews of randomized controlled trials demonstrating effectiveness for allergic rhinitis 1, 9

Expected Benefits

  • Improved symptom scores and quality of life 5, 10
  • Reduced medication requirements 5, 4, 10
  • Prevention of new allergen sensitizations 1, 2, 6
  • Reduced risk of developing asthma (23% reduction in children/adolescents with grass/birch pollen allergy) 6
  • Disease-modifying effects that persist post-treatment 2, 8, 9

Important Limitation

Approximately 35% of randomized controlled trials did not demonstrate efficacy in symptom or medication scores during the first year of treatment 3. Clinical benefits may not be significant until the second year 3.

Allergen Selection

Limit treatment to clinically relevant allergens that correlate with patient history and are confirmed by testing 2

  • Single allergen or limited number of allergens for polysensitized patients 2
  • Avoid mixing multiple non-cross-reacting allergens (associated with anaphylaxis cases) 3

Practical Considerations

Advantages Over SCIT

  • Home administration after initial dose 1
  • No 30-minute post-dose observation required
  • Lower systemic reaction rate 1, 7
  • No fatalities reported 1, 3

Disadvantages

  • Daily dosing requirement (vs. weekly/monthly SCIT injections) 1
  • Aqueous formulations not FDA-approved with non-standardized dosing 1
  • Insurance coverage may be limited compared to SCIT 1
  • Delayed onset of benefit (may require 1-2 years) 3

3, 1, 3, 1, 3, 2, 5, 8, 4, 6, 7, 9, 10

References

Guideline

clinical practice guideline: allergic rhinitis.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015

Guideline

clinical practice guideline: immunotherapy for inhalant allergy.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2024

Guideline

allergen immunotherapy: a practice parameter second update.

Journal of Allergy and Clinical Immunology, 2007

Research

Sublingual Immunotherapy Dosing Regimens: What Is Ideal?

The journal of allergy and clinical immunology. In practice, 2017

Research

EAACI guidelines on allergen immunotherapy: Prevention of allergy.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2017

Research

Study on Effects of Sublingual Immunotherapy in Allergic Rhinitis Patients.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.